Asymmetric dimethylarginine is a marker of poor prognosis and coronary calcium in systemic lupus erythematosus

Journal of Rheumatology

Volumn 34, Issue 7, 2007, Pages 1502-1505

  Kiani, Adnan N ^a   Mahoney, James A ^a   Petri, Michelle ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Asymmetric dimethylarginine; Coronary calcium; Prognosis; Systemic lupus erythematosus

Indexed keywords

CALCIUM; CHOLESTEROL; DOUBLE STRANDED DNA; N(G),N(G) DIMETHYLARGININE; PREDNISONE; RIBONUCLEOPROTEIN ANTIBODY; SM ANTIBODY;

ADULT; AFRICAN AMERICAN; ARTICLE; ATHEROSCLEROSIS; CALCIUM CELL LEVEL; CARDIOVASCULAR RISK; CAUCASIAN; CHOLESTEROL BLOOD LEVEL; CLINICAL FEATURE; CORONARY ARTERY BLOOD FLOW; DISEASE MARKER; ENZYME LINKED IMMUNOSORBENT ASSAY; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; HUMAN; HYPERLIPIDEMIA; LABORATORY DIAGNOSIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; RISK FACTOR; SPIRAL COMPUTER ASSISTED TOMOGRAPHY; SYSTEMIC LUPUS ERYTHEMATOSUS;

ADULT; ANTIBODIES, ANTINUCLEAR; ARGININE; BIOLOGICAL MARKERS; CALCINOSIS; CORONARY ANGIOGRAPHY; CORONARY DISEASE; ETHNIC GROUPS; FEMALE; HUMANS; LIPIDS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MARYLAND; PROGNOSIS; RISK FACTORS;

EID: 34447558298     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Landmesser U, Hornig B, Drexler H. Endothelial function: a critical determinant in atherosclerosis? Circulation 2004;109:1127-33.
2. Moncada S, Higgs A. The 1-arginine-nitric oxide pathway. N Engl J Med 1993;329:200-12.
3. Najbauer J, Johnson BA, Young AL, Aswad DW. Peptides with sequences similar to glycine, arginine-rich motifs in proteins interacting with RNA are efficiently recognized by methyltransferase(s) modifying arginine in numerous proteins. J Biol Chem 1993;268:10501-9.
4. Tang J, Kao PN, Herschman HR. Protein-arginine methyltransferase I, the predominant protein-arginine methyltransferase in cells, interacts with and is regulated by interleukin enhancer-binding factor 3. J Biol Chem 2000;275:19866-76.
5. Zelis R, Mason DT, Braunwald E. A comparison to the effects of vasodilator stimuli on peripheral resistance vessels in normal subjects and in patients with congestive heart failure. J Clin Invest 1968;47:960-70.
6. Johnstone MT, Creager SJ, Scales KM, Cusco JA, Lee BK, Creager MA. Impaired nitric oxide-mediated vasodilation in patients with non-insulin-dependent diabetes mellitus. Circulation 1993;88:2510-6.
7. Park JB, Charbonneau F, Schiffrin EL. Correlation of endothelial function in large and small arteries in human essential hypertension. J Hypertens 2001;19:415-20.
8. Miyazaki H, Matsuoka H, Cooke JP. Endogenous nitric oxide synthase inhibitor. A novel marker of atherosclerosis. Circulation 1999;99:1141-6.
9. Valkonen VP, Päivä H, Salonen JT, Lakka TA, Lehtimäki T, Laakso J. Risk of acute coronary events and serum concentration of asymmetrical dimethylarginine. Lancet 2001;358:2127-8.
10. Lenzen H, Tsikas D, Boger RH. ADMA and the risk for coronary heart disease: the Multicenter CARDIAC Study. Eur J Clin Pharmacol 2005;8:1-5.
11. Bultink IE, Teerlink T, Voskuyl AE. Raised plasma levels of ADMA are associated with cardiovascular events, disease activity and organ damage in patients with SLE. Ann Rheum Dis 2005;64:1362-5.
12. Budoff MJ, Georgiou D, Brody A, Agatston AS, Kennedy J, Wolfkiel C. Ultrafast computed tomography as a diagnostic modality in the detection of coronary artery disease: a multicenter disease: a multicenter study. Circulation 1996;93:898-904.
13. Cooke JP, Singer AH, Tsao P, Zera P, Rowan RA, Billingham ME. Antiatherosclerotic effects of L-arginine in hypercholesterolemic rabbit. J Clin Invest 1992;90:1168-72.
14. Boger RH, Bode-Boger SM, Szuba A, Tsao PS, Chan JR, Tangphao O. ADMA: a novel risk factor for endothelial dysfunction: its role in hypercholesterolemia. Circulation 1998;98:1842-7.
15. Goonasekera CD, Shah V, Rees DD, Dillon MJ. Vascular endothelial cell activation associated with increased plasma asymmetric dimethyl arginine in children and young adults with hypertension: a basis for atheroma? Blood Press 2000;9:16-21.
16. Schnabel R, Blankenberg S, Lubos E, et al. Asymmetric dimethylarginine and the risk of cardiovascular events and death in patients with coronary artery disease: results from the AtheroGene Study. Circ Res 2005;97:e53-9. Epub 2005 Aug 11.
17. Busch M, Fleck C, Wolf G, Stein G. ADMA and SDMA as potential risk factors for cardiovascular and renal outcome in chronic kidney disease - possible candidates for paradoxical epidemiology? Amino Acids 2006;30:225-32.
18. Lu TM, Ding YA, Leu HB, Yin WH, Sheu WHH, Chu KM. Effect of rosuvastatin on plasma levels of asymmetric dimethylarginine in patients with hypercholesterolemia. Am J Cardiol 2004;15:157-61.
19. Nanayakkara P, Teerlink T, Stehouwer C, et al. Plasma asymmetric dimethylarginine (ADMA) concentration is independently associated with carotid intima-media thickness and plasma soluble vascular cell adhesion molecule-1 (sVCAM-1) concentration in patients with mild-to-moderate renal failure. Kidney Int 2005;68:2230-6.
20. Elesber AA, Solomon H, Lennon RJ, et al. Coronary endothelial dysfunction is associated with erectile dysfunction and elevated asymmetric dimethylarginine in patients with early atherosclerosis. Eur Heart J 2006;27:824-31.
21. Yoo-JH, Lee S-C. Elevated levels of plasma homocysteine and ADMA in elderly patients with stroke. Atherosclerosis 2001;158:425-30.
22. Wanby P, Teerlink T, Brudin L, et al. Asymmetric dimethylarginine (ADMA) as a risk marker for stroke and TIA in a Swedish population. Atherosclerosis 2005;185:271-7.
23. Folsom AR, Aleksic N, Catellier D, Juneja AS, Wu KK. C-reactive protein and incident coronary heart disease in the Atherosclerosis Risk In Communities (ARIC) study. Am Heart J 2002;144:233-8.
24. Ito A, Tsao PS, Kimoto M, Ogawa T, Cooke JP. Novel mechanism for endothelial dysfunction: dysregulation of dimethylarginine dimethylaminohydrolase. Circulation 1999;99:3092-5.
25. Boger RH, Syndow K, Borlak J, Tuhm T, Lenzen H, Bode-Boger SM. LDL cholesterol upregulates synthesis of ADMA in human endothelial cells: involvement of S-adenosylmethionine dependent methyl transferases. Circ Res 2000;87:99-105.
26. Kim SH, Lee CK, Lee EY, et al. Serum oxidized low-density lipoproteins in rheumatoid arthritis. Rheumatol Int 2004;24:230-3.
27. Paiva H, Laakso J, Lehtimaki T, Ruokonen I, Laaksonen R. Effect of high-dose statin treatment on plasma concentrations of endogenous nitric oxide synthase inhibitors. J Cardiovasc Pharmacol 2003;41:219-22.
28. Eid HM, Eritsland J, Larsen J, Arnesen H. Increased levels of ADMA in populations at risk for atherosclerosis disease. Effects of pravastatin. Atherosclerosis 2003;166:279-84.
29. McMahon M, Grossman J, FitzGerald J, Hahn B. The novel biomarker pro-inflammatory HDL is associated with carotid artery plaque in women with SLE (abstract). Arthritis Rheum 2006;54 Suppl:S522.